NS5A inhibitors for the treatment of hepatitis C infection

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

(2016) Eric J. Lawitz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correction: Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis

(2016) Hussien Ahmed et al.   ANTIVIRAL THERAPY

Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C

(2016) N. Gamal et al.   Expert Opinion On Drug Safety

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)

(2016) Vincent Leroy et al.   HEPATOLOGY

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

(2016) Fred Poordad et al.   HEPATOLOGY

Hepatitis C genotype 3 disease

(2016) Sarah Kattakuzhy et al.   Hepatology International

Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir

(2016) Kazuaki Chayama et al.   JOURNAL OF GASTROENTEROLOGY

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

(2016) Michael Manns et al.   LANCET INFECTIOUS DISEASES

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection

(2016) Robert J. Fontana et al.   LIVER TRANSPLANTATION

Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation

(2016) S. Ciesek et al.   Transplant Infectious Disease

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

(2015) Stefan Zeuzem et al.   ANNALS OF INTERNAL MEDICINE

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.

(2015) Maria Buti et al.   CLINICAL INFECTIOUS DISEASES

Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C

(2015) Gillian M. Keating   DRUGS

Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

(2015) Anu Osinusi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

(2015) Andrew J. Muir et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection

(2015) Tarek Hassanein et al.   JOURNAL OF HEPATOLOGY

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

(2015) Xavier Forns et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Mark Sulkowski et al.   LANCET

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Eric Lawitz et al.   LANCET

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

(2015) David Roth et al.   LANCET

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

(2015) Masashi Mizokami et al.   LANCET INFECTIOUS DISEASES

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

(2015) Xavier Forns et al.   LIVER INTERNATIONAL

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

(2015) Michael P. Curry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

(2015) Graham R. Foster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

(2015) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

(2015) Susanna Naggie et al.   NEW ENGLAND JOURNAL OF MEDICINE

In VitroandIn VivoAntiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

(2014) Preethi Krishnan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

(2014) Jean–Michel Pawlotsky   GASTROENTEROLOGY

ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

(2014) Pietro Andreone et al.   GASTROENTEROLOGY

Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors

(2014) David R. McGivern et al.   GASTROENTEROLOGY

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

(2014) Michael Manns et al.   LANCET

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

(2014) Peter Ferenci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatitis C virus NS5A inhibitors and drug resistance mutations

(2014) Shingo Nakamoto   WORLD JOURNAL OF GASTROENTEROLOGY

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

(2014) David B. Ascher et al.   Scientific Reports

Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity

(2013) Craig A. Coburn et al.   ChemMedChem

NS5A inhibitors in the treatment of hepatitis C

(2013) Jean-Michel Pawlotsky   JOURNAL OF HEPATOLOGY

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

(2013) Anna S. Lok et al.   JOURNAL OF HEPATOLOGY

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents

(2013) Vincenza Conteduca et al.   JOURNAL OF INFECTION

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

(2013) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In VitroActivity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A

(2012) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir

(2012) Lenore A. Pelosi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events

(2012) M R Higgs et al.   ONCOGENE

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

(2011) R. A. Fridell et al.   JOURNAL OF VIROLOGY

Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action

(2011) P. Targett-Adams et al.   JOURNAL OF VIROLOGY

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes

(2010) U. Chatterji et al.   JOURNAL OF GENERAL VIROLOGY

All Three Domains of the Hepatitis C Virus Nonstructural NS5A Protein Contribute to RNA Binding

(2010) T. L. Foster et al.   JOURNAL OF VIROLOGY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles

(2009) Wagane J. A. Benga et al.   HEPATOLOGY